Bristol Myers Squibb (BMY)

[chmcnfunds]

Bristol-Myers Squibb's (BMY) Nivolumab Receives FDA Orphan Designation for Treatment of Mesothelioma

August 18, 2017 6:24 AM EDT

Bristol-Myers Squibb (NYSE: BMY) Nivolumab received FDA orphan designation for treatment of mesothelioma.
-
Generic Name: nivolumab
Trade Name: N/A
Date Designated: 08/16/2017
Orphan Designation: Treatment of mesothelioma
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Marketing Approval Date: N/A
Approved Labeled Indication:
Exclusivity End Date: N/A
Sponsor: Bristol-Myers Squibb Company
5 Research Parkway
Wallingford, Connecticut 06492
USA

The sponsor address listed is the last reported by the sponsor to OOPD.
___________________________________________________

https://www.streetinsider.com/Corporate+News/Bristol-Myers+Squibbs+%28BMY%29+Nivolumab+Receives+FDA+Orphan+Designation+for+Treatment+of+Mesothelioma/13219235.html

BMY